ABCC4 functional SNP in the 3' splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia.

abstract：PURPOSE:Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS:Patients received ramucir...

journal_title：Cancer chemotherapy and pharmacology

authors： Smit EF,Garon EB,Reck M,Cappuzzo F,Bidoli P,Cohen RB,Gao L,O'Brien LM,Lee P,Zimmermann A,Ferry DR,Melemed AS,Pérol M

更新日期：2018-07-01 00:00:00

abstract：PURPOSE:The purpose of this study was to assess the therapeutic and toxicological effects of cesium chloride (CsCl) administration in mice bearing prostate cancer tumors. METHODS:Three CsCl dose titration studies were completed in tumor-bearing and non-tumor-bearing athymic nude mice. All mice were administered either...

journal_title：Cancer chemotherapy and pharmacology

authors： Low JC,Wasan KM,Fazli L,Eberding A,Adomat H,Guns ES

更新日期：2007-11-01 00:00:00

abstract：PURPOSE:To characterize cobimetinib pharmacokinetics and evaluate impact of clinically relevant covariates on cobimetinib pharmacokinetics. METHODS:Plasma samples (N = 4886) were collected from 487 patients with various solid tumors (mainly melanoma) in three clinical studies (MEK4592g, NO25395, GO28141). Cobimetinib ...

journal_title：Cancer chemotherapy and pharmacology

authors： Han K,Jin JY,Marchand M,Eppler S,Choong N,Hack SP,Tikoo N,Bruno R,Dresser M,Musib L,Budha NR

更新日期：2015-11-01 00:00:00

abstract：:The radiosensitizing activity, acute toxicity, and pharmacokinetics of a new hypoxic cell radiosensitizer, potassium 2-nitroimidazole-1-acetohydroxamate (KIH-802), were compared with those of misonidazole (MISO) and etanidazole (SR-2508). The radiosensitizing activity of KIH-802 was slightly higher than that of MISO a...

journal_title：Cancer chemotherapy and pharmacology

authors： Sasai K,Shibamoto Y,Takahashi M,Zhou L,Hori H,Nagasawa H,Shibata T,Inayama S,Abe M

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines. METHODS:The human endometrial cancer cell lines, HEC-1-A and Ishikawa, were cultured in vitro. MTT assays were comple...

journal_title：Cancer chemotherapy and pharmacology

authors： Navo MA,Smith JA,Gaikwad A,Burke T,Brown J,Ramondetta LM

更新日期：2008-08-01 00:00:00

abstract：:Over the last decade, metronomic chemotherapy has been increasingly considered as an attractive strategy for treating cancer in a variety of settings. Beside pharmaco-economic considerations making metronomics a unique opportunity in low- or middle-income countries, revisiting dosing schedules using continuous low dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Barbolosi D,Ciccolini J,Meille C,Elharrar X,Faivre C,Lacarelle B,André N,Barlesi F

更新日期：2014-09-01 00:00:00

abstract：:The aim of the present study was to investigate whether cisplatin would enhance the radioresponse of a human tumour xenograft when given in different schedules combined with accelerated fractionated radiation therapy. A human squamous carcinoma of the hypopharynx, FaDu, was grown in the thigh of athymic nude mice. Tum...

journal_title：Cancer chemotherapy and pharmacology

authors： Joschko MA,Webster LK,Bishop JF,Groves J,Yuen K,Olver IN,Narayan KN,Ball DL

更新日期：1997-01-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer death in the world. Recently, targeted therapy and anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapy have made great progress in treatment of lung cancer. However, responses to these therapies are variable, influenced b...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Liu S,Tong X,Fan H

更新日期：2018-08-01 00:00:00

abstract：OBJECTIVES:To investigate the effects and potential mechanisms of gambogic acid (GA), a naturally occurring anticancer agent, on the expression and regulation of telomerase in human gastric carcinoma cells. METHODS:GA-induced inhibition of cell proliferation was evaluated by the commonly employed MTT assay on two huma...

journal_title：Cancer chemotherapy and pharmacology

authors： Yu J,Guo QL,You QD,Lin SS,Li Z,Gu HY,Zhang HW,Tan Z,Wang X

更新日期：2006-10-01 00:00:00

abstract：PURPOSE:To investigate the synergistic cytotoxicity of TRAIL in combination with chemotherapeutic agents in A549 cell lines, we systematically evaluated the cytotoxicity of TRAIL alone and TRAIL in combination with cisplatin, paclitaxel (Taxol) or actinomycin D in A549 cell lines in vitro and in vivo, and whether the s...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan QL,Zou WY,Song LH,Wei W

更新日期：2005-02-01 00:00:00

abstract：PURPOSE:The aim of this study was to investigate typical population pharmacokinetic (PK) parameters, potential covariates, and interindividual and residual variabilities of PI-88, a heparanase endoglycosidase enzyme inhibitor being developed for the treatment of cancer. METHODS:A population PK model of PI-88 was devel...

journal_title：Cancer chemotherapy and pharmacology

authors： Hudachek SF,Eckhardt SG,Hicks B,Gustafson DL

更新日期：2010-03-01 00:00:00

abstract：:The present study deals with the influence of some bis(eta 5-cyclopentadienyl)titanium(IV) (titanocene) complexes, mainly represented by titanocene dichloride, on the development of several human gastrointestinal (GI) carcinomas (one stomach, seven colon, four sigmoid, and two rectal adenocarcinomas), all xenografted ...

journal_title：Cancer chemotherapy and pharmacology

authors： Köpf-Maier P

更新日期：1989-01-01 00:00:00

abstract：UNLABELLED:Hypericin, a polycyclic aromatic dianthroquinone, is a natural pigment derived from the plant Hypericum perforatum (St John's Wort). The compound has been synthesized and shown to inhibit the growth of malignant glioma cell lines in vitro via inhibition of protein kinase C. Oral hypericin has entered clinica...

journal_title：Cancer chemotherapy and pharmacology

authors： Fox E,Murphy RF,McCully CL,Adamson PC

更新日期：2001-01-01 00:00:00

abstract：PURPOSE:Defective expression of the mismatch repair protein MSH3 is frequently detected in colon cancer, and down-regulation of its expression was found to decrease sensitivity to platinum compounds or poly(ADP-ribose) polymerase inhibitors (PARPi) monotherapy. We have investigated whether MSH3 transfection in MSH3-def...

journal_title：Cancer chemotherapy and pharmacology

authors： Tentori L,Muzi A,Dorio AS,Dolci S,Campolo F,Vernole P,Lacal PM,Praz F,Graziani G

更新日期：2013-07-01 00:00:00

abstract：PURPOSE:This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas. The goal of the study was to define the maximum tolerated dose (MTD) and to characterize the pharmacokinetics of gefitinib when combined with temozolomide. PATIENTS AND METHODS:Patients were stratified according to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Prados MD,Yung WK,Wen PY,Junck L,Cloughesy T,Fink K,Chang S,Robins HI,Dancey J,Kuhn J

更新日期：2008-05-01 00:00:00

abstract：:The toxic effect of 3'-deoxyadenosine N1-oxide (3'-dANO) on mice, on their different organs, and on Ehrlich ascites tumor cells was studied. In both healthy and tumour-bearing animals, the lethal dose for 10% of the mice receiving i.p. injections (LD10) of 3'-dANO was estimated to be about 300 mg/kg x 4 days in one mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Svendsen KR,Overgaard-Hansen K,Frederiksen S,Engelholm SA,Pedersen NT,Vindeløv LL

更新日期：1992-01-01 00:00:00

abstract：BACKGROUND:There are no clear predictors clinicians can use to determine who is more likely to experience dose-limiting toxicity (DLT) in phase I chemotherapy clinical trials. Many providers are reluctant to refer older adults to phase I trials because of concerns about the development of toxicity. The goal of this stu...

journal_title：Cancer chemotherapy and pharmacology

authors： LoConte NK,Smith M,Alberti D,Bozeman J,Cleary JF,Setala AN,Wodtke G,Wilding G,Holen KD

更新日期：2010-03-01 00:00:00

abstract：PURPOSE:Irinotecan-induced gut toxicity is mediated in part by Toll-Like receptor 4 (TLR4) signalling. The primary purpose of this preclinical study was to determine whether blocking TLR4 signalling by administering (-)-naloxone, a TLR4 antagonist, would improve irinotecan-induced gut toxicity. Our secondary aim was to...

journal_title：Cancer chemotherapy and pharmacology

authors： Coller JK,Bowen JM,Ball IA,Wardill HR,van Sebille YZ,Stansborough RL,Lightwala Z,Wignall A,Shirren J,Secombe K,Gibson RJ

更新日期：2017-02-01 00:00:00

abstract：PURPOSE:To investigate any effect of a CYP3A4 inhibitor (ketoconazole) or inducer (rifampicin) on cediranib steady-state pharmacokinetics in patients with advanced solid tumours. METHODS:In two Phase I, open-label trials, patients received once-daily oral doses of cediranib alone [20 mg (ketoconazole study); 45 mg (ri...

journal_title：Cancer chemotherapy and pharmacology

authors： Lassen U,Miller WH,Hotte S,Evans TR,Kollmansberger C,Adamson D,Nielsen DL,Spicer J,Chen E,Meyer T,Brown K,Rafi R,Sawyer MB

更新日期：2013-02-01 00:00:00

abstract：:The antitumor effects of human lymphoblastoid interferon (HLBI) on human renal cell carcinomas transplanted in nude mice, i.e., KU-2 and RCC-1, were investigated and compared with those on other human tumors, viz. HeLa (cervical carcinoma), KB (nasopharyngeal carcinoma), H.Ep#2 (laryngeal carcinoma), and MX-1 (breast ...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamaoka T,Takada H,Yanagi Y,Kataoka T,Sakurai Y

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:Previous studies have shown that angiotensin peptides stimulate the proliferation of hematopoietic progenitors in vitro, promote survival after exposure to lethal irradiation as well as accelerate the recovery of white blood cells (WBC), i.e., lymphocytes, monocytes and neutrophils, and platelets. These changes...

journal_title：Cancer chemotherapy and pharmacology

authors： Rodgers K,Xiong S,DiZerega GS

更新日期：2003-02-01 00:00:00

abstract：PURPOSE:Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivani...

journal_title：Cancer chemotherapy and pharmacology

authors： Marathe PH,Kamath AV,Zhang Y,D'Arienzo C,Bhide R,Fargnoli J

更新日期：2009-12-01 00:00:00

abstract：:Intravenous (i.v.) administration of sodium thiosulfate reduces the toxicity of cis-diamminedichloroplatinum (II) (CDDP). This effect, which allows the use of increased CDDP doses, has been exploited clinically in the intraperitoneal (i.p.) treatment of intraabdominal tumors. Recently, attempts have been made to treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Aamdal S,Fodstad O,Pihl A

更新日期：1988-01-01 00:00:00

abstract：:Mercaptopurine (6MP) has been the standard drug for maintenance therapy of acute lymphoblastic leukemia. In a multicenter study we investigated whether thioguanine (6TG), which is converted more directly to the cytotoxic thioguanine nucleotides (TGN), offers a therapeutic advantage over 6MP. In this study (COALL-92), ...

journal_title：Cancer chemotherapy and pharmacology

authors： Erb N,Harms DO,Janka-Schaub G

更新日期：1998-01-01 00:00:00

abstract：:Human plasma was incubated with cisplatin over 24 h. Ultrafilterable platinum and platinum reactive with DDTC were determined at regular time intervals during incubation. At each time point more platinum reacted with sodium N,N1-diethyldithiocarbamate (DDTC) than was available as ultrafilterable platinum. At 24 h 70% ...

journal_title：Cancer chemotherapy and pharmacology

authors： Hegedüs L,van der Vijgh WJ,Klein I,Kerpel-Fronius S,Pinedo HM

更新日期：1987-01-01 00:00:00

abstract：:Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting...

journal_title：Cancer chemotherapy and pharmacology

authors： Aapro MS,Alberts DS

更新日期：1981-01-01 00:00:00

abstract：:Nine children with soft tissue sarcomas, five of them rhabdomyosarcomas with initial metastatic disease, (one patient, partial response, one patient), refractory primary, (two patients, relapse, five patients) were treated with a combination of high-dose VP16 (100 mg/m2 daily for 5 days) and cisplatin (40 mg/m2 daily ...

journal_title：Cancer chemotherapy and pharmacology

authors： Grabois M,Frappaz D,Bouffet E,Carrie C,Bouhour D,Philip T,Brunat-Mentigny M

更新日期：1994-01-01 00:00:00

abstract：INTRODUCTION:Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to p...

journal_title：Cancer chemotherapy and pharmacology

authors： van Andel L,Rosing H,Zhang Z,Hughes L,Kansra V,Sanghvi M,Tibben MM,Gebretensae A,Schellens JHM,Beijnen JH

更新日期：2018-01-01 00:00:00

abstract：:Paclitaxel is used as a single agent, and in combination with other drugs, as a standard of care in the treatment of squamous cell carcinoma of the head and neck (SCCHN). However, the use of paclitaxel for therapy of SCCHN may be accompanied by serious side effects. Paclitaxel is a known cytotoxic inhibitor of cell pr...

journal_title：Cancer chemotherapy and pharmacology

authors： Jaglowski JR,Zagon IS,Stack BC Jr,Verderame MF,Leure-duPree AE,Manning JD,McLaughlin PJ

更新日期：2005-07-01 00:00:00

abstract：:Interleukin 12 (IL-12) is a heterodimeric cytokine with a number of biological effects that are consistent with its potential role as an antitumor agent. The antimetastatic and antitumor activities of IL-12 have been demonstrated in a number of murine tumor models. Both the inhibition of established experimental pulmo...

journal_title：Cancer chemotherapy and pharmacology

authors： Brunda MJ,Luistro L,Rumennik L,Wright RB,Dvorozniak M,Aglione A,Wigginton JM,Wiltrout RH,Hendrzak JA,Palleroni AV

更新日期：1996-01-01 00:00:00